Table 1.

Characteristics of cohort overall and according to vaccine doses received at beginning of study period during Omicron outbreak (1 Jan 2022).

	1 dose		2 doses		3 doses		Total
N	19,849		1,575,405		457,869		2,053,123
Mean age (SD)	59.5 (14.6)		58.3 (13.0)		61.4 (13.9)		59.0 (13.3)
Age group (years)
40–49	31.4 %	6,228	30.8 %	484,912	25.6 %	117,306	29.6 %	608,446
50–59	24.5 %	4,855	27.1 %	426,748	23.0 %	105,182	26.1 %	563,785
60–69	19.9 %	3,950	21.6 %	340,206	20.4 %	93,342	21.3 %	437,498
70–79	12.5 %	2,479	13.1 %	207,029	19.5 %	89,126	14.6 %	298,634
80–89	8.1 %	1,605	6.0 %	95,009	8.9 %	40,767	6.7 %	137,381
90+	3.7 %	732	1.4 %	21,501	2.6 %	12,146	1.7 %	34,379
% Women (N)	49.5 %	9,817	51.0 %	803,835	52.5 %	240,164	51.3 %	1,053,816
Proportion above median Australian socioeconomic index % (N)	66.5 %	13,202	73.6 %	1,159,061	82.8 %	379,041	75.6 %	1,551,304
% At least one comorbidity (N)	12.0 %	2,390	10.3 %	161,686	13.4 %	61,268	11.0 %	225,344
COVID-19 vaccine brand
Astra Zeneca (ChAdOx1) % (N)	32.3 %	6,415	46.8 %	737,301	0.9 %	4,241
Moderna (mRNA-1273) % (N)	4.8 %	953	0.8 %	12,033	13.7 %	62,655
Pfizer (BNT162b2) % (N)	62.2 %	12,349	52.4 %	825,301	85.4 %	390,865
Other % (N)	0.7 %	132	0.1 %	770	0.0 %	108
Mean weeks since receipt of last dose (SD)	13.4 (10.0)		16.8 (5.0)		2.4 (2.7)